AGWCA
JAZZ icon

Annis Gardner Whiting Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$757 – 816
2026
Q1 		$757 Hold
4
– – ﹤0.01% 1178
2025
Q4 		$680 Buy
+4
New +$613 ﹤0.01% 1090

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's JAZZ Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 4 shares — an estimated $757 sold.

Annis Gardner Whiting Capital Advisors first reported a position in JAZZ in Q4 2025 and held it in 2 quarters. The position peaked at $757 in Q1 2026. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 4 Jazz Pharmaceuticals shares in Q2 2026, an estimated $757.
  • Annis Gardner Whiting Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Annis Gardner Whiting Capital Advisors's Jazz Pharmaceuticals position peaked at $757 in Q1 2026.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.